Lindén IB - Search Results

1

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production.

Nissinen E, Kaheinen P, Penttilä KE, Kaivola J, Lindén IB. Nissinen E, et al. Among authors: linden ib. Eur J Pharmacol. 1997 Dec 11;340(2-3):287-94. doi: 10.1016/s0014-2999(97)01431-3. Eur J Pharmacol. 1997. PMID: 9537825

2

Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.

Nissinen E, Lindén IB, Schultz E, Pohto P. Nissinen E, et al. Among authors: linden ib. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):262-6. doi: 10.1007/BF00173538. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1407012

3

Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.

Lindén IB, Nissinen E, Etemadzadeh E, Kaakkola S, Männistö P, Pohto P. Lindén IB, et al. J Pharmacol Exp Ther. 1988 Oct;247(1):289-93. J Pharmacol Exp Ther. 1988. PMID: 3171977

4

Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.

Nissinen E, Lindén IB, Schultz E, Kaakkola S, Männistö PT, Pohto P. Nissinen E, et al. Among authors: linden ib. Eur J Pharmacol. 1988 Aug 24;153(2-3):263-9. doi: 10.1016/0014-2999(88)90614-0. Eur J Pharmacol. 1988. PMID: 3181288

5

Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.

Bäckström R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Linden IB, Männistö PT, Kaakkola S, et al. Bäckström R, et al. Among authors: linden ib. J Med Chem. 1989 Apr;32(4):841-6. doi: 10.1021/jm00124a017. J Med Chem. 1989. PMID: 2704029

6

Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase.

Männistö PT, Kaakkola S, Nissinen E, Linden IB, Pohto P. Männistö PT, et al. Among authors: linden ib. Life Sci. 1988;43(18):1465-71. doi: 10.1016/0024-3205(88)90258-5. Life Sci. 1988. PMID: 3185103

7

Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation.

Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Lindén IB. Haikala H, et al. Among authors: linden ib. J Cardiovasc Pharmacol. 1995 May;25(5):794-801. doi: 10.1097/00005344-199505000-00016. J Cardiovasc Pharmacol. 1995. PMID: 7630157

8

Antioxidant properties of nitecapone are potentiated by glutathione.

Nissinen E, Lindén IB, Pohto P. Nissinen E, et al. Among authors: linden ib. Biochem Mol Biol Int. 1995 Feb;35(2):387-95. Biochem Mol Biol Int. 1995. PMID: 7663394

9

Protection by nitecapone against sodium taurocholate-induced damage to cultured gastric cells.

Tu Y, Ranta S, Nissinen E, Lindén IB. Tu Y, et al. Among authors: linden ib. Dig Dis Sci. 1993 Apr;38(4):701-7. doi: 10.1007/BF01316803. Dig Dis Sci. 1993. PMID: 7681749

10

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan.

Haikala H, Kaheinen P, Levijoki J, Lindén IB. Haikala H, et al. Among authors: linden ib. Cardiovasc Res. 1997 Jun;34(3):536-46. doi: 10.1016/s0008-6363(97)00057-6. Cardiovasc Res. 1997. PMID: 9231037

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters